Atrium Therapeutics(RNA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RNA Atrium Therapeutics

交易中 07-06 09:50:42 EDT

13.03

-0.62

-4.54%

最高13.61	最低13.03	成交量2.08万
今开13.60	昨收13.65	日振幅4.25%
总市值2.23亿	流通市值2.13亿	总股本1,711万
成交额27.98万	换手率0.13%	流通股本1,637万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RNA","market":"US","secType":"STK","nameCN":"Atrium Therapeutics","latestPrice":13.03,"timestamp":1783345821513,"preClose":13.65,"halted":0,"volume":20781,"delay":0,"changeRate":-0.045421245421245496,"floatShares":16374250,"shares":17105600,"eps":-3.430739,"marketStatus":"交易中","change":-0.62,"latestTime":"07-06 09:50:42 EDT","open":13.6,"high":13.61,"low":13.03,"amount":279788.401584,"amplitude":0.042491,"askPrice":13.24,"askSize":100,"bidPrice":13.01,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.430739,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1783368000000},"marketStatusCode":2,"adr":0,"listingDate":1591934400000,"exchange":"NASDAQ","adjPreClose":13.65,"preHourTrading":{"tag":"盘前","latestPrice":13.6,"preClose":13.65,"latestTime":"09:29 EDT","volume":141,"amount":1912.7000385,"timestamp":1783344599999,"change":-0.05,"changeRate":-0.003663,"amplitude":0.190476},"postHourTrading":{"tag":"盘后","latestPrice":13.65,"preClose":13.65,"latestTime":"16:38 EDT","volume":3349,"amount":45706.85,"timestamp":1783024690123,"change":0,"changeRate":0,"amplitude":0.005128},"volumeRatio":1.069154,"impliedVol":0.1535,"impliedVolPercentile":0.1534},"requestUrl":"/m/hq/s/RNA/wiki","defaultTab":"wiki","newsList":[{"id":"2640188675","title":"RNA技术落地肾病研发 礼来(LLY)敲定19亿美元投资前沿生物管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2640188675","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640188675?lang=zh_cn&edition=full","pubTime":"2026-06-03 22:56","pubTimestamp":1780498602,"startTime":"0","endTime":"0","summary":"金吾财讯 | 总部位于波士顿的生物技术企业 Ascidian Therapeutics 周三披露合作协议，与礼来 敲定总额上限 19 亿美元的研发授权合作，依托前者 RNA 外显子编辑平台共同开发肾脏病创新药物。本次交易是礼来近期密集产业布局的又一落地项目。依托 GLP-1 减重产品带来的充沛现金流，药企持续重金布局 RNA、细胞治疗等前沿生物技术，通过外部合作补齐肾病管线，完善多元化新药储备。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/MjU4MmU0MDcxNDc2ODE0Nzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MjU4MmU0MDcxNDc2ODE0Nzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301131","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1069344957.HKD","SG9999017495.SGD","LU1291159041.SGD","LU2089284900.SGD","LU2271345857.HKD","LU0096364046.USD","LU0158827781.USD","LU0353189680.USD","LU0320765992.SGD","LU1629891620.HKD","SG9999015978.USD","BK4599","LU0094547139.USD","LU1232071149.USD","LU0109394709.USD","LU1267930730.SGD","LU2471134796.USD","BK4007","LU2168563687.JPY","LU1127390331.HKD","LU1983299246.USD","LU0640476718.USD","LU0787776722.HKD","LU1023059063.AUD","BK4585","LU0353189763.USD","LU2237443978.SGD","LU0354030438.USD","LU2360106947.USD","LU1868837136.USD","SGXZ57979304.SGD","LU2168564495.EUR","IE0005OL40V9.USD","LU1057294990.SGD","ELIS","IE00BFTCPJ56.SGD","IE00B7KXQ091.USD","LU2211815571.USD","IE00B4R5TH58.HKD","LU0385154629.USD","LU2023250504.SGD","LU2456880835.USD","SG9999018857.SGD","LU0203201768.USD","LLYX","BK4505","LU2237438978.USD","LU0786609619.USD","LU1323610961.USD","LU0320765059.SGD","IE0002141913.USD","LU2028103732.USD","SG9999018865.SGD","IE00BK4W5L77.USD","LU2491049909.HKD","SG9999015945.SGD","IE00BJJMRX11.SGD","IE0001KFT4U8.USD","SG9999014898.SGD","LU0471298694.HKD","LU1988902786.USD","LU2746668974.SGD","LU2108987350.USD","LU2471134523.USD","IE00B1BXHZ80.USD","LU1366192091.USD","LU2471134879.HKD","IE00BJT1NW94.SGD","LU2089283258.USD","LU0882574139.USD","BK4534","LU2023250330.USD","LU1093756325.SGD","IE00BFSS7M15.SGD","LU0889565916.HKD","LU0203202063.USD","LU2471134952.CNY","LU2896262040.SGD","LU1868837300.USD","LU0097036916.USD","SG9999013999.USD","LU2265009873.SGD","LU0114720955.EUR","LU1720051108.HKD","LU1712237335.SGD","LU2756315664.SGD","SG9999014880.SGD","LU0079474960.USD","IE00BN29S564.USD","LU2237443895.HKD","BK4139","LU0823416689.USD","LU2111349929.HKD","LU2237443465.HKD","IE00BKPKM429.USD","LU2552382215.SGD","IE0004445015.USD","LU2089984988.USD","LU2168564222.USD","LU0943347566.SGD","SGXZ81514606.USD","LU1868836591.USD","LU1061106388.HKD","LU0106261372.USD","IE00B1XK9C88.USD","LU1974910355.USD","LU2236285917.USD","LU1623119135.USD","LU2087625088.SGD","LLY","LU0882574055.USD","LU2112291526.USD","LU2468319806.SGD","LU0820561818.USD","LU1989771016.USD","IE00BKDWB100.SGD","LLYZ","LU0289739699.SGD","LU2417539215.USD","SG9999001176.USD","BK4588","LU0432979614.USD","IE00BWXC8680.SGD","IE00B775H168.HKD","LU0061475181.USD","SG9999015986.USD","LU1280957306.USD","LU2357305700.SGD","LU2264538146.SGD","LU0133085943.USD","SG9999014906.USD","LU2063271972.USD","LU2237443382.USD","LU1145028129.USD","IE00BJLML261.HKD","LU0256863902.USD","LU0158827948.USD","LU1720051017.SGD","LU0225283273.USD","LU0708995401.HKD","LU0006306889.USD","LU1868836914.USD","IE0004445239.USD","LU2750360997.AUD","IE00BK4W5M84.HKD","LU0238689110.USD","LU2491050154.USD","BK4533","LU1814569148.SGD","IE00B4JS1V06.HKD","SG9999015952.SGD","LU0820561909.HKD","LU2168564065.EUR","LU0210536198.USD","LU0234572021.USD","LU2213496289.HKD","LU2462157665.USD","LU2602419157.SGD","BK4516","LU0323591593.USD","LU0316494557.USD","LU2023251221.USD","SG9999014914.USD","LU0354030511.USD","LU2237443549.SGD","LU0471298777.SGD","LU2552382132.HKD","LU2746668461.USD","LU0198837287.USD","LU1064131342.USD","SG9999001176.SGD","RNA","SGXZ99366536.SGD","IE0009355771.USD","LU1035775433.USD","LU1551013425.SGD","LU0672654240.SGD","LU2461242641.AUD","LU1551013342.USD","IE00BJJMRY28.SGD","LU1548497426.USD","IE0009354923.USD","LU0823434740.USD","LU0109391861.USD","LU0058720904.USD","LLII","LU0823434583.USD","LU0456855351.SGD","LU2168564149.EUR","LU1804176565.USD","LU2361045086.USD","BK4581","LU1093756168.USD","LU0683600562.USD","LU0466842654.USD","SGXZ31699556.SGD","ELIL","LU0964807845.USD","IE00BFSS8Q28.SGD","LU2106854487.HKD","LU2552382058.USD","LU0266013472.USD","LU2237443622.USD","LU0417517546.SGD","GB00BDT5M118.USD","LU2361044949.HKD","LU0256863811.USD","LU1917777945.USD","LU2361044865.SGD","LU2756315318.SGD","IE00BJJMRZ35.SGD","LU2750360641.GBP","IE00B2B36J28.USD","SGXZ51526630.SGD","LU0122379950.USD","LU0689472784.USD","LU1868836757.USD","LU0820562030.AUD","LU2491050071.SGD","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635035758","title":"Atrium Therapeutics Q1净亏损1660万美元，BMS里程碑付款支撑收入","url":"https://stock-news.laohu8.com/highlight/detail?id=2635035758","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635035758?lang=zh_cn&edition=full","pubTime":"2026-05-15 23:41","pubTimestamp":1778859660,"startTime":"0","endTime":"0","summary":"　　Atrium Therapeutics公布2026年第一季度财报。公司报告期内净亏损为1663万美元，合每股亏损0.97美元。作为对比，公司在作为Avidity Biosciences子公司期间的2025年同期净亏损为745万美元，合每股亏损0.44美元。需要说明的是，由于Atrium于2026年2月27日才完成从Avidity的分拆独立上市，本期财务数据不宜直接与历史同期进行比较。　　Atrium于2月27日正式作为独立公司登陆纳斯达克。ATR 1072的IND申请预计于2026年下半年提交，ATR 1086的IND申请预计于2027年提交。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-15/doc-inhxyyie6355365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE0009354923.USD","BK4139","BK4585","BK4505","BK4539","LENZ","BK4588","BMS","BK4007","RNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138398611","title":"Leerink Partners首予Atrium Therapeutics“跑赢大盘”评级，目标价25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1138398611","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138398611?lang=zh_cn&edition=full","pubTime":"2026-05-15 18:08","pubTimestamp":1778839712,"startTime":"0","endTime":"0","summary":"Leerink Partners近日发布研究报告，首次覆盖生物技术公司Atrium Therapeutics，并给予“跑赢大盘”的评级，同时设定25美元的目标股价。\n这一评级反映了该机构对公司前景的积极看法。分析师认为，Atrium Therapeutics在相关治疗领域拥有发展潜力，其股价未来有上行空间。目标价的设定基于对该公司业务和财务状况的评估。\n市场将密切关注这一新评级对Atrium Therapeutics股票走势的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","BK4585","BK4139","BK4505","BK4588","RNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119762769","title":"Atrium Therapeutics公布第一季度运营费用达3691.5万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119762769","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119762769?lang=zh_cn&edition=full","pubTime":"2026-05-15 05:18","pubTimestamp":1778793492,"startTime":"0","endTime":"0","summary":"生物制药公司Atrium Therapeutics Inc披露了其第一季度财务数据，显示该季度运营费用总计3691.5万美元。这一数字反映了公司在研发及日常运营方面的持续投入。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","IE0009354923.USD","RNA","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635995057","title":"港股异动 | 云顶新耀(01952)涨超3% 近期公布mRNA肿瘤疫苗EVM16首次人体数据 公司RNA平台进一步验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2635995057","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635995057?lang=zh_cn&edition=full","pubTime":"2026-05-14 15:24","pubTimestamp":1778743450,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，云顶新耀涨超3%，截至发稿，涨3.48%，报31.48港元，成交额1.33亿港元。消息面上，云顶新耀近期宣布，公司在2026年美国癌症研究协会年会上公布自研mRNA个性化肿瘤治疗性疫苗EVM16单药治疗及联合PD-1抑制剂治疗晚期实体瘤的首次人体临床试验数据。方正证券指出，RNA平台中，现货型TAA mRNA疫苗EVM14实现中美新药临床IND双获批并完成首例患者入组给药；mRNA自体生成CAR-T项目EVM18完成非人灵长类动物概念验证并推进临床开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK4505","RNA","BK1161","BK4588","IE0009354923.USD","BK1583","BK4585","VXUS","BK1574","159646","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630932874","title":"【券商聚焦】方正证券维持云顶新耀(01952)“强烈推荐”评级 指RNA平台进一步验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2630932874","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630932874?lang=zh_cn&edition=full","pubTime":"2026-04-28 11:09","pubTimestamp":1777345757,"startTime":"0","endTime":"0","summary":"金吾财讯 | 方正证券发布研报指，云顶新耀 在AACR大会发布mRNA肿瘤疫苗EVM16首次人体数据，RNA平台进一步验证。商业化成果显著，2025年公司实现收入17.07亿元人民币，大幅增长141.51%。截至2025年12月31日，公司现金储备达27.31亿元人民币。盈利预测方面，方正证券预计2026-2028年公司销售收入分别为39.56/54.52/71.41亿元人民币，同比增长131.78%/37.83%/30.98%；归母净利润分别为2.53/6.65/11.47亿元人民币，维持“强烈推荐”评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980112","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","RNA","601901"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105218816","title":"Atrium Therapeutics获施贵宝心血管合作1500万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1105218816","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105218816?lang=zh_cn&edition=full","pubTime":"2026-04-23 20:04","pubTimestamp":1776945856,"startTime":"0","endTime":"0","summary":"Atrium Therapeutics宣布，根据其与施贵宝达成的全球心血管领域合作协议，公司已成功获得一笔1500万美元的里程碑付款。此次付款标志着双方合作取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989771016.USD","IE00B2B36J28.USD","LU1074936037.SGD","BMY","LU2242646821.SGD","LU0267386448.USD","LU1571399168.USD","LU0114720955.EUR","LU2125154778.USD","LU1261432733.SGD","BK4588","BK4559","LU0225771236.USD","LU1291159041.SGD","LU0237698245.USD","IE00BFXG1179.USD","LU1718418525.SGD","IE00BJJMRZ35.SGD","BK4532","LU1585245621.USD","LU1868836757.USD","LU2125154935.USD","LU1983299246.USD","LU0321505868.SGD","LU1868837300.USD","LU2133065610.SGD","LU1430594728.SGD","LU0432979614.USD","LU1093756325.SGD","LU0061475181.USD","LU1670711123.USD","LU0456855351.SGD","LU0882574055.USD","IE0009354923.USD","IE00BJT1NW94.SGD","IE0002141913.USD","BK4007","LU0306806265.USD","IE0009355771.USD","LU1323610961.USD","LU0321505439.SGD","LU1868836591.USD","LU0225284248.USD","LU1868836914.USD","IE00BFTCPJ56.SGD","LU1883839398.USD","BK4534","LU0868494617.USD","LU2360032135.SGD","BK4581","LU2242652126.USD","IE00BSNM7G36.USD","LU1670710588.SGD","LU1670710661.SGD","LU1093756168.USD","LU0096364046.USD","BK4585","LU0985481810.HKD","LU1670711040.USD","BK4139","BK4505","LU1032466523.USD","RNA","LU0306807586.USD","LU1868837136.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181426981","title":"施贵宝将全面资助Atrium Therapeutics合作项目未来所有临床、注册及商业化活动","url":"https://stock-news.laohu8.com/highlight/detail?id=1181426981","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181426981?lang=zh_cn&edition=full","pubTime":"2026-04-23 20:03","pubTimestamp":1776945801,"startTime":"0","endTime":"0","summary":"根据最新合作协议条款，施贵宝（Bristol Myers Squibb）将承担与Atrium Therapeutics合作项目后续所有临床开发、注册申报及商业化活动的全部资金。这一安排标志着双方战略合作进入新阶段，由施贵宝主导推进项目全球化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1074936037.SGD","IE00BFXG1179.USD","BK4007","BK4139","LU0882574055.USD","LU1585245621.USD","LU0432979614.USD","LU1868837300.USD","BMY","LU0114720955.EUR","IE0002141913.USD","LU1430594728.SGD","LU0225284248.USD","LU0456855351.SGD","LU1571399168.USD","LU1670711123.USD","LU1868836591.USD","LU1868837136.USD","LU2125154778.USD","LU0237698245.USD","LU1868836757.USD","LU2133065610.SGD","BK4588","LU1093756325.SGD","LU2242652126.USD","LU1883839398.USD","IE0009355771.USD","RNA","LU0321505439.SGD","BK4581","LU0306806265.USD","LU1093756168.USD","LU1261432733.SGD","LU1323610961.USD","LU1670711040.USD","LU2125154935.USD","LU0868494617.USD","IE00B2B36J28.USD","LU1718418525.SGD","LU0985481810.HKD","LU1032466523.USD","LU1670710661.SGD","BK4534","BK4505","LU0306807586.USD","BK4532","IE00BJJMRZ35.SGD","LU0061475181.USD","LU1989771016.USD","LU0225771236.USD","IE00BFTCPJ56.SGD","LU0096364046.USD","LU1670710588.SGD","LU0321505868.SGD","LU1868836914.USD","IE00BSNM7G36.USD","LU0267386448.USD","LU2360032135.SGD","IE0009354923.USD","LU1291159041.SGD","IE00BJT1NW94.SGD","LU1983299246.USD","LU2242646821.SGD","BK4585","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123489677","title":"Atrium Therapeutics 有望获得高达13.5亿美元研发里程碑付款、8.25亿美元商业里程碑付款及分层特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1123489677","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123489677?lang=zh_cn&edition=full","pubTime":"2026-04-23 20:02","pubTimestamp":1776945720,"startTime":"0","endTime":"0","summary":"生物技术公司Atrium Therapeutics Inc（RNA）宣布，其与制药巨头施贵宝（BMY）达成的合作协议中，包含丰厚的潜在财务回报。根据协议条款，Atrium有资格获得最高可达13.5亿美元的研发里程碑付款。\n此外，协议还涵盖了商业成功方面的激励。该公司有望进一步获得高达8.25亿美元的基于销售额的商业里程碑付款。除了这些一次性付款，合作协议还规定Atrium将获得基于产品净销售额的分层特许权使用费。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868836591.USD","IE00BSNM7G36.USD","LU1670710588.SGD","BMY","LU1585245621.USD","IE00BFXG1179.USD","BK4585","BK4505","LU0061475181.USD","LU1670710661.SGD","LU2125154778.USD","LU0321505439.SGD","LU0096364046.USD","LU1868837136.USD","LU2133065610.SGD","LU1093756168.USD","LU0985481810.HKD","LU0225284248.USD","LU1032466523.USD","LU1571399168.USD","LU1670711040.USD","LU1430594728.SGD","BK4007","LU0432979614.USD","LU0868494617.USD","LU1261432733.SGD","LU1670711123.USD","LU2242646821.SGD","LU2242652126.USD","LU1074936037.SGD","BK4559","IE0009354923.USD","IE00BJJMRZ35.SGD","LU0237698245.USD","LU1868836757.USD","LU0225771236.USD","LU1989771016.USD","LU1983299246.USD","LU1868837300.USD","IE0009355771.USD","LU1868836914.USD","IE00BFTCPJ56.SGD","LU0306807586.USD","LU1323610961.USD","LU1883839398.USD","BK4534","LU0882574055.USD","LU1718418525.SGD","LU0456855351.SGD","LU2360032135.SGD","IE00B2B36J28.USD","LU0306806265.USD","LU1291159041.SGD","LU1093756325.SGD","BK4581","BK4532","LU0267386448.USD","RNA","IE0002141913.USD","IE00BJT1NW94.SGD","BK4139","LU2125154935.USD","LU0321505868.SGD","BK4588","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614834631","title":"Wave Life Sciences Ltd.盘中异动 大幅上涨5.09%报15.28美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614834631","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614834631?lang=zh_cn&edition=full","pubTime":"2026-02-27 03:16","pubTimestamp":1772133396,"startTime":"0","endTime":"0","summary":"北京时间2026年02月27日03时16分，Wave Life Sciences Ltd.股票出现波动，股价急速上涨5.09%。截至发稿，该股报15.28美元/股，成交量228.111万股，换手率1.23%，振幅7.29%。Wave Life Sciences Ltd.股票所在的生物技术行业中，整体跌幅为1.98%。Wave Life Sciences Ltd.公司简介：WAVE Life Sciences Ltd 是一家临床阶段的生物技术公司，专注于释放 RNA 药物的广泛潜力，靶向核糖核酸 ，以改变人类健康。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602270316369542259a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602270316369542259a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RNA","BK4588","WVE","BK4585","BK4505","IE0009354923.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137428854","title":"《新英格兰医学杂志》发布Delpacibart Etedesiran治疗1型强直性肌营养不良的MARINA® 1/2期试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1137428854","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137428854?lang=zh_cn&edition=full","pubTime":"2026-02-19 06:01","pubTimestamp":1771452074,"startTime":"0","endTime":"0","summary":"《新英格兰医学杂志》近日正式刊载了针对1型强直性肌营养不良治疗的创新疗法Delpacibart Etedesinan（研发代号Del-Desiran）在MARINA® 1/2期临床试验中所取得的研究数据。该试验旨在评估这一候选药物的安全性与初步疗效，为罕见神经肌肉疾病的治疗领域提供了新的科学依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","RNA","BK4588","BK4585","IE0009354923.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612406701","title":"Wave Life Sciences Ltd.盘中异动 早盘大幅拉升5.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612406701","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612406701?lang=zh_cn&edition=full","pubTime":"2026-02-18 22:34","pubTimestamp":1771425265,"startTime":"0","endTime":"0","summary":"北京时间2026年02月18日22时34分，Wave Life Sciences Ltd.股票出现异动，股价快速上涨5.72%。Wave Life Sciences Ltd.股票所在的生物技术行业中，整体跌幅为0.45%。Wave Life Sciences Ltd.公司简介：WAVE Life Sciences Ltd 是一家临床阶段的生物技术公司，专注于释放 RNA 药物的广泛潜力，靶向核糖核酸 ，以改变人类健康。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021822342597a675a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021822342597a675a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RNA","WVE","BK4585","BK4588","BK4505","SNSE","BK4139","BK4007","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604113059","title":"WAVE Life Sciences：聚焦RNA编辑与RNAi疗法的前沿先锋","url":"https://stock-news.laohu8.com/highlight/detail?id=2604113059","media":"药研前瞻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604113059?lang=zh_cn&edition=full","pubTime":"2026-01-19 15:25","pubTimestamp":1768807551,"startTime":"0","endTime":"0","summary":"其GalNAc-SpiNA siRNA可实现一年一次或两次给药。通过RNA编辑纠正突变有望同时改善肺和肝的病理状态。RestorAATion-2 临床试验正在进行中。400 毫克的 MAD 数据预计将于 2026 年第一季度公布，600 毫克的 SAD 和 MAD 数据预计将于 2026 年公布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011916052297a25e6e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011916052297a25e6e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4505","IE0009354923.USD","BK4133","WVE","BK4007","WAVE","RNA","BK4585","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603573916","title":"管线成果超预期 获数千万港币里程碑付款！晶泰科技(02228)赋能AI+RNA新药RTX-117获中美临床批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2603573916","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603573916?lang=zh_cn&edition=full","pubTime":"2026-01-14 09:23","pubTimestamp":1768353831,"startTime":"0","endTime":"0","summary":"ReviR 将继续完成 RTX-117 的后续临床开发，晶泰科技有权参与该管线的销售分成及后续授权收益分成。RTX-117 为晶泰科技与 ReviR 深度合作的一系列研发管线中首个里程碑成果，其临床前数据及临床获批速度均超出双方预期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4550","02228","IE0009354923.USD","LU1280957306.USD","IE00B3S45H60.SGD","LU1366192091.USD","RTX","BK1617","BK4139","LU0640476718.USD","LU0320765646.SGD","LU1585245621.USD","BK4588","BK4505","BK4566","LU0787776722.HKD","LU1929549753.HKD","BK4585","BK1141","LU1430594728.SGD","BK4187","IE00B775SV38.USD","LU1162221912.USD","RNA","LU0683600562.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2518208788","title":"B of A Securities：维持Avidity Biosciences(RNA.US)评级，由买入调整至买入评级, 目标价由51.00美元调整至48.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518208788","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518208788?lang=zh_cn&edition=full","pubTime":"2025-03-11 01:02","pubTimestamp":1741626170,"startTime":"0","endTime":"0","summary":"B of A Securities：维持Avidity Biosciences(RNA.US)评级，由买入调整至买入评级, 目标价由51.00美元调整至48.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/11010248641317.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518779220","title":"Wave Life Sciences Ltd.盘中异动 早盘股价大跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518779220","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518779220?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:48","pubTimestamp":1741614536,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时48分，Wave Life Sciences Ltd.股票出现异动，股价大幅跳水5.00%。Wave Life Sciences Ltd.股票所在的生物技术行业中，整体涨幅为0.26%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Mineralys Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为2691.51%、610.55%、93.48%，振幅较大的相关个股有Scisparc Ltd.、Impact Biomedical, Inc.、Trevi Therapeutics, Inc.，振幅分别为40.24%、28.59%、25.35%。Wave Life Sciences Ltd.公司简介：WAVE Life Sciences Ltd正在释放RNA药物的广泛潜力，也被称为寡核苷酸，它以核糖核酸为目标，改变人类健康。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021485698a2a1a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021485698a2a1a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","BK4007","WVE","RNA","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518274848","title":"Applied Dna Sciences, Inc.盘中异动 急速拉升5.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518274848","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518274848?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:39","pubTimestamp":1741613968,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时39分，Applied Dna Sciences, Inc.股票出现异动，股价大幅拉升5.78%。Applied Dna Sciences, Inc.股票所在的生命科学行业中，整体跌幅为0.39%。Applied Dna Sciences, Inc.公司简介：Applied DNA Sciences Inc 是一家开发和商业化生产和检测脱氧核糖核酸和核糖核酸技术的生物技术公司。该公司以Applied DNA Sciences、SigNature分子标签、SigNature T分子标签、fiberTyping、SigNify等品牌提供的产品和服务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021392898a29eac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021392898a29eac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RNA","DNA","BK4505","BK4121","APDN","BK4109","BK4585","BK4583","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518812428","title":"Avidity Biosciences, Inc.2024财年实现净利润-3.22亿美元，同比减少51.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518812428","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518812428?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:00","pubTimestamp":1741449622,"startTime":"0","endTime":"0","summary":"3月9日，Avidity Biosciences, Inc.公布财报，公告显示公司2024财年净利润为-3.22亿美元，同比减少51.89%；其中营业收入为10.90百万美元，同比增加14.02%，每股基本收益为-2.89美元。从资产负债表来看，Avidity Biosciences, Inc.总负债1.39亿美元，其中短期债务3.84百万美元，资产负债比为11.26，流动比率为0.16。机构评级：截至2025年3月9日，当前有11家机构对Avidity Biosciences, Inc.目标价做出预测，其中目标均价为68.09美元，其中最低目标价为57.00美元，最高目标价为96.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000037abef96ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000037abef96ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517467349","title":"Avidity Biosciences(RNA.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价70.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517467349","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517467349?lang=zh_cn&edition=full","pubTime":"2025-03-08 06:32","pubTimestamp":1741386747,"startTime":"0","endTime":"0","summary":"Avidity Biosciences(RNA.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价70.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08063248605337.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517944311","title":"Wave Life Sciences Ltd.盘中异动 股价大跌5.08%报10.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517944311","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517944311?lang=zh_cn&edition=full","pubTime":"2025-03-06 00:46","pubTimestamp":1741193179,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日00时46分，Wave Life Sciences Ltd.股票出现波动，股价急速跳水5.08%。截至发稿，该股报10.66美元/股，成交量34.3525万股，换手率0.22%，振幅6.50%。Wave Life Sciences Ltd.股票所在的生物技术行业中，整体涨幅为0.99%。Wave Life Sciences Ltd.公司简介：WAVE Life Sciences Ltd正在释放RNA药物的广泛潜力，也被称为寡核苷酸，它以核糖核酸为目标，改变人类健康。RNA药物平台PRISMTM结合多种模式、化学创新和对人类遗传学的深刻见解，提供治疗罕见和流行疾病的科学突破。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306004620989d64bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306004620989d64bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","WVE","BK4588","RNA","BK4505","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.atriumtherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0681},{"period":"1month","weight":0.1143},{"period":"3month","weight":0.0156},{"period":"6month","weight":-0.2417},{"period":"1year","weight":-0.2417},{"period":"ytd","weight":-0.2417}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":-0.0195},{"period":"3month","weight":0.1356},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2004},{"period":"ytd","weight":0.0922}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Atrium Therapeutics, Inc.于2025年9月30日根据特拉华州法律注册成立，是Avidity Biosciences, Inc.的直接全资子公司。该公司是一家生物制药公司，致力于开创向心脏输送RNA疗法的先河，旨在改变心肌病患者个人的护理标准。利用最初在Avidity开发的专有RNA递送平台，该公司将单克隆抗体的组织选择性与寡核苷酸的精确度相结合，以靶向以前无法药物治疗的疾病的遗传驱动因素。Atrium专注于解决影响全球数百万人的基因驱动心肌病，其开发管道包括针对与严重心脏病相关的特定基因驱动因素的项目。在稳健的临床前和积极的临床数据支持下，该公司定位于重新定义精准心脏病学中的治疗范式。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.025613},{"month":2,"riseRate":0.666667,"avgChangeRate":0.084173},{"month":3,"riseRate":0.4,"avgChangeRate":-0.00029},{"month":4,"riseRate":0.4,"avgChangeRate":-0.058331},{"month":5,"riseRate":0.4,"avgChangeRate":-0.018927},{"month":6,"riseRate":0.8,"avgChangeRate":0.113151},{"month":7,"riseRate":0.5,"avgChangeRate":0.027674},{"month":8,"riseRate":0.666667,"avgChangeRate":0.073003},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.048121},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.000506},{"month":11,"riseRate":0.666667,"avgChangeRate":0.096576},{"month":12,"riseRate":0.666667,"avgChangeRate":0.110632}],"exchange":"NASDAQ","name":"Atrium Therapeutics","nameEN":"Atrium Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Atrium Therapeutics(RNA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Atrium Therapeutics(RNA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Atrium Therapeutics,RNA,Atrium Therapeutics股票,Atrium Therapeutics股票老虎,Atrium Therapeutics股票老虎国际,Atrium Therapeutics行情,Atrium Therapeutics股票行情,Atrium Therapeutics股价,Atrium Therapeutics股市,Atrium Therapeutics股票价格,Atrium Therapeutics股票交易,Atrium Therapeutics股票购买,Atrium Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Atrium Therapeutics(RNA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Atrium Therapeutics(RNA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}